English, Article edition: A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal Therapy: For Advanced Breast Cancer in Postmenopausal Patients Jon Karnon; Trefor Jones

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119613
Physical Description
  • article
Language
  • English

Edition details

Title
  • A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal Therapy: For Advanced Breast Cancer in Postmenopausal Patients
Author
  • Jon Karnon
  • Trefor Jones
Physical Description
  • article
Notes
  • Background: Letrozole is a third-generation aromatase inhibitor that is a feasible alternative to tamoxifen as a first-line hormonal therapy for patients with advanced breast cancer. Objective: This paper presents the results of an economic evaluation comparing letrozole and tamoxifen as first-line hormonal therapies in postmenopausal women diagnosed with advanced breast cancer. Perspective: UK National Health Service. Design: A decision model (Markov process) was built describing possible patient pathways from the point of diagnosis to death. The model was populated using patient-specific clinical trial data, data from the existing literature, and expert opinion. Stochastic analyses of the model were undertaken, whereby the majority of the input parameters were described as probability distributions to represent the uncertainty about their true value. Costs were presented in year 2000 values. Results: The baseline results showed that letrozole is a cost-effective alternative to tamoxifen with a mean incremental cost per life-year gained of Lstg 2342, whilst the incremental cost increases to just over Lstg 10 Conclusions: The results of the economic analysis indicate that letrozole is a cost-effective alternative first-line therapy compared with tamoxifen for postmenopausal women with advanced breast cancer, achieving additional life-years with a modest increase in costs.
  • Advanced-breast-cancer, Aromatase-inhibitors, Cost-analysis, Estrogen receptor modulators, Letrozole, Menopause, Tamoxifen, Pharmacoeconomics
  • RePEc:wkh:phecon:v:21:y:2003:i:7:p:513-525
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment